king pharmaceuticals limited
king pharmaceuticals limited Company Information
Company Number
FC019337
Next Accounts
1156 days late
Shareholders
-
Group Structure
View All
Industry
Non-specialised wholesale trade
+1Registered Address
branch registration, refer to parent registry
Website
-king pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KING PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 0.43x industry multiple (adjusted for size and gross margin).
king pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KING PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-318.4k and a 3.91x industry multiple (adjusted for size and gross margin).
king pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KING PHARMACEUTICALS LIMITED at £23.2m based on Net Assets of £9.8m and 2.38x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
King Pharmaceuticals Limited Overview
King Pharmaceuticals Limited is a converted/closed company that was located in refer to parent registry. Founded in December 1995, it's largest shareholder was unknown. The last turnover for King Pharmaceuticals Limited was estimated at £0.
Upgrade for unlimited company reports & a free credit check
King Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded King Pharmaceuticals Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 0 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - King Pharmaceuticals Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - King Pharmaceuticals Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- King Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 11729 weeks, this is more cash available to meet short term requirements (17 weeks)
- - King Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.4%, this is a lower level of debt than the average (57.8%)
- - King Pharmaceuticals Limited
- - Industry AVG
KING PHARMACEUTICALS LIMITED financials
King Pharmaceuticals Limited's latest turnover from April 2020 is estimated at 0 and the company has net assets of £9.8 million. According to their latest financial statements, we estimate that King Pharmaceuticals Limited has no employees and maintains cash reserves of £9.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1,684,844 | 3,923,362 | 7,245,508 | 11,652,342 | 10,242,803 | 6,845,119 | 4,909,899 | 3,830,437 | 3,127,432 | ||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | 1,208,500 | 2,590,625 | 2,015,562 | 5,569,219 | 6,133,058 | 4,467,818 | 3,266,341 | 2,599,785 | 2,394,177 | ||
| Gross Profit | 476,344 | 1,332,737 | 5,229,946 | 6,083,123 | 4,109,745 | 2,377,301 | 1,643,558 | 1,230,652 | 733,255 | ||
| Admin Expenses | 441,541 | 481,763 | 482,568 | 1,536,110 | 1,129,100 | 1,050,291 | 1,173,710 | 895,396 | 709,972 | ||
| Operating Profit | 34,803 | 850,974 | 4,747,378 | 4,547,013 | 2,980,645 | 1,327,010 | 469,848 | 335,256 | 23,283 | ||
| Interest Payable | 272 | 259 | 281 | ||||||||
| Interest Receivable | 204,441 | 84,154 | 13,092 | 11,691 | 3,363 | 1,524 | 689 | 401 | 293 | ||
| Pre-Tax Profit | 239,244 | 935,128 | 4,760,198 | 4,558,704 | 2,984,008 | 1,328,534 | 470,537 | 335,657 | 23,576 | ||
| Tax | -45,456 | -186,259 | -951,758 | -953,621 | -683,184 | -317,752 | -117,472 | -86,227 | -4,944 | ||
| Profit After Tax | 193,788 | 748,869 | 3,808,440 | 3,605,083 | 2,300,824 | 1,010,782 | 353,065 | 249,430 | 18,632 | ||
| Dividends Paid | 1,750,000 | 606,061 | 404,040 | ||||||||
| Retained Profit | 193,788 | 748,869 | 3,808,440 | 3,605,083 | 550,824 | 404,721 | -50,975 | 249,430 | 18,632 | ||
| Employee Costs | 750 | 750 | |||||||||
| Number Of Employees | |||||||||||
| EBITDA* | 34,803 | 851,038 | 4,747,571 | 4,547,206 | 2,980,838 | 1,327,203 | 469,977 | 335,256 | 23,283 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 64 | 257 | 450 | 643 | 836 | ||||||
| Intangible Assets | |||||||||||
| Investments & Other | |||||||||||
| Debtors (Due After 1 year) | |||||||||||
| Total Fixed Assets | 64 | 257 | 450 | 643 | 836 | ||||||
| Stock & work in progress | 146,580 | 167,864 | 203,855 | 734,611 | 2,400,105 | 2,033,411 | 1,170,279 | 580,244 | 346,686 | 559,631 | 781,901 |
| Trade Debtors | 49,710 | 56,092 | 226,476 | 527,164 | 1,066,123 | 1,890,730 | 2,223,474 | 1,658,988 | 1,197,138 | 769,221 | 650,576 |
| Group Debtors | |||||||||||
| Misc Debtors | 16,528 | 2,780,474 | 2,579,884 | 13,628 | 2,738,930 | 23,516 | 27,654 | 9,582 | 111,619 | 65,828 | |
| Cash | 9,621,438 | 9,944,335 | 6,905,849 | 6,127,627 | 6,219,542 | 4,307,022 | 2,806,459 | 880,677 | 707,200 | 617,368 | 167,850 |
| misc current assets | |||||||||||
| total current assets | 9,817,728 | 10,184,819 | 10,116,654 | 9,969,286 | 9,699,398 | 10,970,093 | 6,223,728 | 3,147,563 | 2,260,606 | 2,057,839 | 1,666,155 |
| total assets | 9,817,728 | 10,184,819 | 10,116,654 | 9,969,286 | 9,699,462 | 10,970,350 | 6,224,178 | 3,148,206 | 2,261,442 | 2,057,839 | 1,666,155 |
| Bank overdraft | 962 | ||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 36,708 | 65,163 | 67,915 | 47,687 | 125,546 | 418,211 | 1,353,399 | 978,975 | 1,255,432 | 817,964 | 702,529 |
| Group/Directors Accounts | |||||||||||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 4,986 | 35,974 | 78,282 | 144,931 | 546,117 | 5,332,780 | 3,256,503 | 1,105,725 | 347,175 | 430,282 | 403,463 |
| total current liabilities | 42,656 | 101,137 | 146,197 | 192,618 | 671,663 | 5,750,991 | 4,609,902 | 2,084,700 | 1,602,607 | 1,248,246 | 1,105,992 |
| loans | |||||||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | 100,000 | 100,000 | |||||||||
| provisions | 104 | 103 | 103 | 103 | 103 | 167 | 217 | ||||
| total long term liabilities | 104 | 103 | 103 | 103 | 103 | 167 | 217 | 100,000 | 100,000 | ||
| total liabilities | 42,656 | 101,137 | 146,301 | 192,721 | 671,766 | 5,751,094 | 4,610,005 | 2,084,867 | 1,602,824 | 1,348,246 | 1,205,992 |
| net assets | 9,775,072 | 10,083,682 | 9,970,353 | 9,776,565 | 9,027,696 | 5,219,256 | 1,614,173 | 1,063,339 | 658,618 | 709,593 | 460,163 |
| total shareholders funds | 9,775,072 | 10,083,682 | 9,970,353 | 9,776,565 | 9,027,696 | 5,219,256 | 1,614,173 | 1,063,339 | 658,618 | 709,593 | 460,163 |
| Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2016 | Apr 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | 34,803 | 850,974 | 4,747,378 | 4,547,013 | 2,980,645 | 1,327,010 | 469,848 | 335,256 | 23,283 | ||
| Depreciation | 64 | 193 | 193 | 193 | 193 | 129 | |||||
| Amortisation | |||||||||||
| Tax | -45,456 | -186,259 | -951,758 | -953,621 | -683,184 | -317,752 | -117,472 | -86,227 | -4,944 | ||
| Stock | -21,284 | -35,991 | -530,756 | -1,665,494 | 366,694 | 863,132 | 590,035 | 233,558 | -212,945 | -222,270 | 781,901 |
| Debtors | -22,910 | -2,934,330 | -100,098 | 2,027,297 | -3,549,909 | 2,382,670 | 560,348 | 479,922 | 325,880 | 164,436 | 716,404 |
| Creditors | -28,455 | -2,752 | 20,228 | -77,859 | -292,665 | -935,188 | 374,424 | -276,457 | 437,468 | 115,435 | 702,529 |
| Accruals and Deferred Income | -30,988 | -42,308 | -66,649 | -401,186 | -4,786,663 | 2,076,277 | 2,150,778 | 758,550 | -83,107 | 26,819 | 403,463 |
| Deferred Taxes & Provisions | -104 | 1 | -64 | -50 | 217 | ||||||
| Cash flow from operations | 573,781 | -176,069 | 1,899,700 | 1,488,872 | 3,672,409 | 778,014 | 594,148 | 449,117 | -373,974 | ||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | |||||||||||
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | |||||||||||
| Other Short Term Loans | |||||||||||
| Long term loans | |||||||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | -100,000 | 100,000 | |||||||||
| share issue | |||||||||||
| interest | 204,441 | 84,154 | 12,820 | 11,691 | 3,104 | 1,243 | 689 | 401 | 293 | ||
| cash flow from financing | 204,441 | 84,154 | 12,820 | 11,691 | 3,114 | 1,243 | -99,311 | 401 | 541,824 | ||
| cash and cash equivalents | |||||||||||
| cash | -322,897 | 3,038,486 | 778,222 | -91,915 | 1,912,520 | 1,500,563 | 1,925,782 | 173,477 | 89,832 | 449,518 | 167,850 |
| overdraft | 962 | ||||||||||
| change in cash | -323,859 | 3,038,486 | 778,222 | -91,915 | 1,912,520 | 1,500,563 | 1,925,782 | 173,477 | 89,832 | 449,518 | 167,850 |
king pharmaceuticals limited Credit Report and Business Information
King Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for king pharmaceuticals limited by selecting its closest rivals, whether from the industry sector, other mature companies, companies in Region Area area or any other competitors across 12 key performance metrics.
king pharmaceuticals limited Ownership
KING PHARMACEUTICALS LIMITED group structure
King Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
KING PHARMACEUTICALS LIMITED
FC019337
king pharmaceuticals limited directors
King Pharmaceuticals Limited currently has 2 directors. The longest serving directors include Mr Terence Sullivan (Oct 2000) and Mrs Pauline Clarke (Mar 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Terence Sullivan | Republic Of Ireland | 77 years | Oct 2000 | - | Director |
| Mrs Pauline Clarke | 59 years | Mar 2020 | - | Director |
P&L
April 2020turnover
0
0%
operating profit
-318.4k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
April 2020net assets
9.8m
-0.03%
total assets
9.8m
-0.04%
cash
9.6m
-0.03%
net assets
Total assets minus all liabilities
Similar Companies
king pharmaceuticals limited company details
company number
FC019337
Type
Other
industry
46900 - Non-specialised wholesale trade
82990 - Other business support service activities n.e.c.
incorporation date
December 1995
age
30
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
April 2020
previous names
N/A
accountant
MHA MACINTYRE HUDSON
auditor
-
address
branch registration, refer to parent registry
Bank
NATIONAL WESTMINSTER BANK PLC, NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
king pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to king pharmaceuticals limited. Currently there are 2 open charges and 0 have been satisfied in the past.
king pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for KING PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
king pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
